-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MorphoSys AG (NASDAQ:MOR) Receives $14.48 Consensus Price Target From Brokerages
MorphoSys AG (NASDAQ:MOR) Receives $14.48 Consensus Price Target From Brokerages
Shares of MorphoSys AG (NASDAQ:MOR – Get Rating) have been assigned an average rating of "Hold" from the eight analysts that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $9.97.
A number of equities analysts have recently issued reports on the stock. The Goldman Sachs Group lowered shares of MorphoSys from a "neutral" rating to a "sell" rating in a research report on Friday, December 16th. JPMorgan Chase & Co. lowered shares of MorphoSys from a "neutral" rating to an "underweight" rating and set a $2.90 price objective on the stock. in a research report on Tuesday, January 3rd. Morgan Stanley lowered shares of MorphoSys from an "equal weight" rating to an "underweight" rating in a research report on Friday. Deutsche Bank Aktiengesellschaft lowered shares of MorphoSys from a "hold" rating to a "sell" rating in a research report on Monday, October 24th. Finally, JMP Securities lowered their price objective on shares of MorphoSys from $32.00 to $15.00 and set a "market outperform" rating on the stock in a research report on Friday, November 18th.
Get MorphoSys alerts:Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Group AG raised its stake in shares of MorphoSys by 122.7% during the 3rd quarter. UBS Group AG now owns 5,141 shares of the company's stock worth $26,000 after buying an additional 2,832 shares during the last quarter. Virtu Financial LLC acquired a new position in MorphoSys in the 2nd quarter valued at about $53,000. Citadel Advisors LLC acquired a new position in MorphoSys in the 3rd quarter valued at about $101,000. OLD Mission Capital LLC acquired a new position in MorphoSys in the 2nd quarter valued at about $195,000. Finally, Endurant Capital Management LP acquired a new position in MorphoSys in the 3rd quarter valued at about $344,000. Institutional investors and hedge funds own 2.05% of the company's stock.
MorphoSys Trading Up 7.8 %
MOR stock opened at $3.88 on Wednesday. MorphoSys has a twelve month low of $3.17 and a twelve month high of $9.32. The company's 50 day moving average is $4.08 and its two-hundred day moving average is $4.77. The stock has a market cap of $531.28 million, a P/E ratio of -0.55 and a beta of 0.96.MorphoSys (NASDAQ:MOR – Get Rating) last announced its earnings results on Wednesday, November 16th. The company reported ($0.91) earnings per share (EPS) for the quarter. The business had revenue of $96.56 million for the quarter. MorphoSys had a negative return on equity of 1,157.24% and a negative net margin of 357.89%. During the same quarter in the previous year, the business posted ($0.97) EPS. On average, equities research analysts predict that MorphoSys will post -2.99 earnings per share for the current year.
MorphoSys Company Profile
(Get Rating)
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
Featured Stories
- Get a free copy of the StockNews.com research report on MorphoSys (MOR)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Here's Why Snap Stock Can Double in 2023
- Which Streaming Service Stock is Best in 2023?
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.
据Marketbeat报道,追踪MorPhoSys AG(纳斯达克代码:MOR-GET)的八位分析师给予该公司股票的平均评级为“持有”。五名投资分析师对该股的评级为卖出,一名分析师给出了持有评级,两名分析师给出了该公司的买入评级。过去一年跟踪该股的分析师平均12个月目标价为9.97美元。
一些股票分析师最近发布了关于该股的报告。在12月16日星期五的一份研究报告中,高盛将MorphSys的股票评级从中性下调到了卖出。摩根大通将Morphy Sys的股票评级从中性下调至减持,并为该股设定了2.90美元的目标价。在1月3日星期二的一份研究报告中。上周五,摩根士丹利在一份研究报告中将Morphesys的股票评级从“持平”下调至“减持”。在10月24日周一的一份研究报告中,德意志银行Aktiengesellschaft将MorPhoSys的股票评级从持有下调至卖出。最后,JMP证券在11月18日星期五的一份研究报告中将MorPhoSys的股票目标价从32.00美元下调至15.00美元,并对该股设定了“市场表现优于大盘”的评级。
到达睡眠症警报:机构资金流入和流出
对冲基金和其他机构投资者最近对他们在该公司的头寸进行了调整。瑞银集团(UBS Group AG)在第三季度增持了Morphesys的股份122.7%。瑞银集团(UBS Group AG)在上个季度又购买了2,832股瑞银股票后,目前持有5,141股该公司股票,价值26,000美元。Virtu Financial LLC在第二季度收购了MorPhoSys的一个新头寸,价值约53,000美元。Citadel Advisors LLC在第三季度收购了MorPhoSys的一个新头寸,价值约为101,000美元。旧使命资本有限责任公司在第二季度收购了MorPhoSys的一个新头寸,价值约19.5万美元。最后,耐久资本管理有限公司在第三季度收购了MorPhoSys的一个新头寸,价值约为344,000美元。机构投资者和对冲基金持有该公司2.05%的股票。
Morphosys交易上涨7.8%
周三,MOR的股价开盘报3.88美元。Morphosys的12个月低点为3.17美元,12个月高位为9.32美元。该公司的50日移动均线切入位在4.08美元,200日移动均线切入位在4.77美元。该股市值为5.3128亿美元,市盈率为-0.55,贝塔系数为0.96。Morphosys(纳斯达克:MOR-GET评级)最近一次公布财报是在11月16日星期三。该公司公布了该季度每股收益(EPS)(0.91美元)。该业务本季度的收入为9656万美元。Morphosys的净资产回报率为负1,157.24%,净利润率为负357.89%。在去年同一季度,该业务公布了每股收益(0.97美元)。平均而言,股票研究分析师预测MorPhoSys本年度的每股收益将达到2.99美元。
Morphosys公司简介
(获取评级)
Morphosys AG是一家商业阶段的生物制药公司,致力于为美国癌症和自身免疫性疾病患者发现、开发治疗性抗体并将其商业化。它提供了Tafasitamab,一种用于治疗B细胞恶性肿瘤的抗体,包括弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤和边缘区淋巴瘤。
专题报道
- 免费获取StockNews.com关于MorPhoSys的研究报告(MOR)
- 理想汽车会成为2023年最不招人恨的中国电动汽车股吗?
- 以下是Snap股票在2023年翻一番的原因
- 哪种流媒体服务股票是2023年最好的?
- MarketBeat:回顾中的一周01/02-01/06
- 为什么CrowdStrike的股价举步维艰?
接收MorPhoSys Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收对MorphSys和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧